Clinical Trials Logo
  1. Home
  2. Metastatic Solid Tumors
  3. NCT00149019

Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.

Metastatic Solid Tumors Clinical Trial

Official title:
Innovative Approaches for Targeted Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.

Clinical Trial Summary

Patients with resistant metastatic solid tumors failing all conventional modalities who are eligible for immunotherapy by bispecific antibodies.

First step: NST Second step: Patients with tumor cells expressing positive Her-2Neu and/or EpCAM with residual or recurrent disease following NST will be candidates for donor lymphocytes immunotherapy using bispecific antibodies.

Patients with no matched donor available, expressing positive Her-2Neu and/or EpCAM tumor cells, will be eligible for donor mismatched lymphocytes using in-vitro rIL-2 activated allogeneic lymphocytes targeted to the tumor by bispecific antibodies, Her-2Neu and/or EpCAM.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00149019
Study type Interventional
Source Hadassah Medical Organization
Contact
Status Withdrawn
Phase Phase 2
Start date May 2002
Completion date September 2005
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03993873 - Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET Phase 1/Phase 2
Recruiting NCT05494918 - First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors Phase 1
Completed NCT02281409 - Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01928459 - Phase 1b Trial of BGJ398/BYL719 in Solid Tumors Phase 1
Completed NCT01449370 - Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer Phase 1
Recruiting NCT06031441 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT03059823 - A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors Phase 1
Terminated NCT03573544 - This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. Phase 1/Phase 2
Active, not recruiting NCT03893955 - A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00878423 - Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors Phase 1
Recruiting NCT03093116 - A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Phase 1/Phase 2
Terminated NCT03854227 - A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors Phase 1
Recruiting NCT04094610 - A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Phase 1/Phase 2
Active, not recruiting NCT01543763 - Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors Phase 1
Terminated NCT02228811 - A Study of DCC-2701 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05853367 - Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) Phase 1
Completed NCT02097810 - Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. Phase 1
Recruiting NCT05836324 - A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03910530 - A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT00148993 - Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors Phase 1/Phase 2